Alan W. Dunton
Independent DirectorDr. Alan W. Dunton, BSc (BioChem) Hons, M.D., has been an Independent Director of Oragenics, Inc. since April 2011. He serves as Non-Executive Director of Recce Pharmaceuticals Ltd since July 14, 2020 and is its Chief Medical Advisor. Dr. Dunton served as an Independent Non-Executive Director of Regeneus Ltd since April 29, 2019 until February 24, 2021. He has been an Independent Director of CorMedix Inc. since March 1, 2019. Dr. Dunton served as Head of Research, Development & Regulatory Affairs at Purdue Products L.P since February 28, 2017 until March 2018 and served as its Head of Research & Development since November 24, 2015 until February 28, 2017. Dr. Dunton has been Consultant of Purdue Pharma L.P. since April 12, 2018. He served as Senior Vice President of Research, Development and Regulatory Affairs at Purdue Pharma L.P. since November 19, 2015 until March 2018, with responsibilities for overall research strategy and development programs. Dr. Dunton has been a Senior Consultant of Derma Sciences Inc. since 2012. He serves as a Consultant of Davierius LLC. He served as Chief Medical Officer of Marina Biotech, Inc. since September 1, 2011 until June 21, 2016. Dr. Dunton is the Principal Owner of Danerius, LLC. Dr. Dunton founded Danerius, LLC in 2006 and served as its Principal. He served as the Chief Executive Officer of Panacos Pharmaceuticals Inc. from January 8, 2007 to March 2009 and its President from July 31, 2007 to March 2009. He served as a Managing Director of Panacos from March 2009 to January 2011. He has devoted his career to the discovery and development of new prescription and over the counter (OTC) drug products. Dr. Dunton has great experience in clinical research, drug development and the regulatory process, highlighted by leadership roles in the development and approval of the prescription drugs Levaquin®, TOPAMAX®, Reminyl®, Regranex® and Risperdal®, as well as the successful OTC product Aleve®. Dr. Dunton has hands-on drug discovery, development and regulatory experience across all functional areas and has played a key role in the development of more than 20 products through to regulatory approval, including the successful OTC pain drug AleveTM. Dr. Dunton served as the Chief Executive Officer and President of MetaPhore Pharmaceuticals Inc., from February 2003 to 2006. He served as the President of Emisphere Technologies, Inc. from January 2002 to December 2002 and also served as its Chief Executive Officer and Chief Operating Officer. He served as the President and Managing Director of Janssen Research Foundation, a subsidiary of Johnson & Johnson from 1999 to December 2001 and served in Executive positions at Hoffmann La Roche Inc., CIBA-GEIGY (now Novartis) and Syntex Corporation. He served as Group Vice President for Development at R.W. Johnson Pharmaceutical Research Institute. From 1998 to 1999, he served as Group Vice President of Global Clinical Research and Development of Janssen. He served as Vice President of Global Clinical Research and Development at the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. From 1994 to 2001, Dr. Dunton served as Senior Executive in various capacities within the Pharmaceuticals Group of Johnson & Johnson, where he was responsible for the development and regulatory activities for such blockbuster drugs as Levaquin(R), Topamax(R) and Risperdal(R) line extensions. In his career he served clinical research and clinical pharmacology positions at Syntex Corporation, Ciba-Geigy Corporation, Hoffmann La Roche Inc. and Revlon Health Care Group. He is a seasoned pharmaceutical executive with extensive Board-level experience. He served as the Chairman and Director of EpiCept Corporation/EpiCept, Inc. since January 5, 2012. He served as the Non-Executive Chairman and Director of ActivBiotics Inc. from December 2005 to 2007. He serves as a Director of Palatin, Inc. He is Member of Advisory Board of Cytogel Pharma, LLC. He was a Director of Panacos Pharmaceuticals Inc since January 8, 2007. He has been an Independent Director of Palatin Technologies Inc. since June 22, 2011. He served as Director of Sancilio & Company, Inc. since July 2012. He had been a Director of Sancilio Pharmaceuticals Company, Inc since May 2011. He served as Non-Executive Director of Bionomics Ltd since September 29, 2015 until July 4, 2016. He serves as a Member of the Advisory Board at Rosa Pharmaceuticals. He served as a Director at Targacept, Inc. since October 2006. He served as Director of Emisphere Technologies. He served as a Director of VWR International LLC since May 17, 2006. He served as a Director of VWR Funding Inc. since May 2006, Durata Therapeutics, Inc. (formerly, Vicuron Pharmaceuticals Inc.) from September 20, 2004 to 2005 and Adams Respiratory Therapeutics Inc. (acquired by Reckitt Benckiser Group plc) since November 8, 2006. From 2004 until 2005, Dr. Dunton served as a Member of the Board of Directors of Vicuron Pharmaceuticals until it was acquired by Pfizer, Incorporated in 2002. Dr. Dunton served as a Director of MetaPhore Pharmaceuticals, Inc. He served as a Director of Catalyst Biosciences, Inc. until August 20, 2015. He served as a Director of Medicinova Inc. from May 11, 2006 to January 28, 2011. He is a recipient of the prestigious Nellie Westerman Prize from the American Federation of Clinical Research for his work in medical ethics, specifically in the area of HIV research. He is a recognized leader in drug development and clinical research. His teaching appointments include Stanford University School of Medicine, Newark Beth Israel Medical Center and NYU Medical Center. Dr. Dunton is also a diplomat of the American Board of Internal Medicine and licensed to practice medicine in New Jersey and New York. He completed his Fellowship in Clinical Pharmacology at Cornell University/Medical College/New York Hospital. He Holds a BS in Biochemistry from State University School of New York at Buffalo. Dr. Dunton received his M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center.
Positions
- Company NameOragenics, Inc.Stock CodeOGENPositionIndependent DirectorColleagues
- JHJanet HuffmanCEO, President, Secretary & Treasurer
- CLCharles L. PopeIndependent Chairman of the Board
- JSJohn SpencerChief Financial Officer
- JPJames P. KellyChief Medical Officer
- WFWilliam Franklin PeacockChief Clinical Officer
- FWFrederick W. TellingIndependent Director
- RCRobert Clayton KoskiIndependent Director
- JPJohn P. GandolfoIndependent Director
- Company NamePalatin Technologies, Inc.Stock CodePTNPositionIndependent DirectorColleagues
- CSCarl SpanaCo-Founder, President, CEO & Director
- JKJohn K. A. PrendergastIndependent Non-Executive Chairman
- STStephen T. WillsCFO, COO, Executive VP, Treasurer & Secretary
- BMBurns McClellanVice President of Investor Relations
- SAStephen A. SlusherChief Legal Officer
- JEJames E. HattersleySenior Vice President of Business Development
- AWAlan W. DuntonIndependent Director
- AMArlene M. MorrisIndependent Director
- RCRaymond C. RosenMember of Female Sexual Dysfunction Expert Panel
